Endocrine Abstracts

Background: Graves’ hyperthyroidism is treated with anti-thyroid drugs (ATD) for 12–18 months, after which ~50% of patients remain euthyroid. Risk factors predicting relapse are: male gender, younger age, orbitopathy, large goitres, severe hyperthyroidism at diagnosis and smoking. Recent reports suggest measurement of TBII at ATD cessation is useful in predicting risk of relapse. Aim: To prospectively investigate whether TBII levels at cessation of ATD therapy are us...

Introduction: Hyperthyroid Graves’ Disease affects 3% of women and 0.5% of men over a lifetime, with only 50% of patients experiencing remission following antithyroid drug therapy. The humoral immune response involves the production of Thyroid Stimulating Hormone Receptor antibodies (TRAbs) from plasma cells. This study aims to provide proof of principle that Daratumumab, a monoclonal antibody targeting cell-surface CD-38 on plasma cells, could modulate the immune respons...